

Kristina Källén
Lund University, Medical Faculty,
Department of Clinical Sciences Lund-Helsingborg
Postal address:
Svartbrödragränden 3-5
251 87 Helsingborg
Sweden
Email: kristina.kallen@med.lu.se
Mobile: +46732033167
Web address: <http://www.med.lu.se/klinvetlund/neurologi>

Employment

Supervisor

Clinical Sciences, Helsingborg
Lund University
Helsingborg, Sweden
2015 Mar 1 → present

Neurology, Lund

Lund University
Lund, Sweden
2015 Sept 21 → present

Project manager

Clinical Epilepsy Research
Lund University
Lund, Sweden
2016 Aug 11 → present

Affiliated researcher

Epilepsy Center
Lund University
Lund, Sweden
2019 Feb 28 → present

Deputy head of department

Department of Clinical Sciences, Lund
Lund University
Lund, Sweden
2019 Apr 8 → present

Certifications

1988 MD degree, University of Gothenburg, Sweden.
1990 Authorized Physician in Sweden.
1995 Registered Specialist in Neurology in Sweden.
1996 Specialist examination in Neurology under the Auspices of the Swedish Society of Neurology and the Swedish Society of Medicine.
1999 October 16th PhD in Neurology, Faculty of Medicine, Lund University
2008 Associate Professor in Neurology, Faculty of Medicine, Lund University
2021 Professor, internal medicine - Neurology, Faculty of Medicine, Lund University

Foreign research appointment:

2000-2001 Research Fellowship. Epilepsy Section, Department of Neurology, the Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Current Academic positions

Professorship in neurology at Lund University, Medical Faculty, Department of Clinical Sciences in Lund, Division of Clinical Sciences Helsingborg

Previous Honorary Commitments

Treasurer Swedish Neurological Society 1999-2001
President Swedish Neurological Society 2002-2004
Steering Committee, Swedish National Epilepsy Registry 2002-2015
Board member Swedish Epilepsy Society 1999-2014
President Swedish Epilepsy Society 2010-2013, Chapter International League Against Epilepsy

Current Clinical positions

Current expert appointments

2012 Senior Consultat, Department of Specialized Medicine-Neurology,
General Hospital in Helsingborg
2001 Senior Consultant, Department of Neurology, Rehabilitation, Geriatric and Memory
Medicin,
Skåne University Hospital, Lund
1998 Coordinator Lund Epilepsy Surgery Team
LIPUS (Läkarnas Institut för Professionell Utveckling i Sverige)
The Swedish Ethics Review Authority

RESEARCH

Scientific supervision:

Principle supervisor of Maria Strandberg for her doctoral thesis "Advanced clinical MRI for better outcome in epilepsy surgery – focusing on prediction of verbal memory decline". Dissertation defence performed at Lund University, November 29, 2014.
Principle supervisor of neuropsychologist Hanna Ljung for her doctoral thesis "Predictors of Verbal Memory Deficits from Temporal Lobe Surgery in Epilepsy. Improving patient selection by investigation of methods used for predicting verbal memory following surgery".
Dissertation defence performed at Lund University, November 17, 2018.
Principle supervisor of MD Patrik Olsson for his doctoral thesis "Generic drug switch in epilepsy - pharmacokinetic and clinical aspects". Dissertation defence performed at Lund University, June 2021.
Principle supervisor of MD Kevin Pearsson for his doctoral thesis "Epilepsy surgery in tuberous sclerosis complex : Utilisation, satisfaction, and outcomes". Dissertation defence performed at Lund University December 5th 2024.
Principle supervisor of PhD students with ongoing projects:
Ariadni Zampeli, specialist in neurology. PhD project Accepted at LU 2017.
Johan Hellgren, MD. Phd project accepted by LU 2020.
Supervisor of 11 master degree projects 2012 - 2025.
Opponent at doctoral dissertation:
Simone Frizell Reiter thesis "Psychiatric disease, adverse social aspects, and quality of life in women and men with epilepsy related to pregnancy". University of Bergen, Norway, November 11, 2016.
Reviewer at the Half-time seminar.
Sorina Gorcenco, Clinical and genetic studies on patients and families with ataxias. March 19, 2021.
Margareta Lang, Head computed tomography for prediction of neurological outcome after cardiac arrest. April 18 2023
Member of evaluating committee at doctoral dissertation:
Malin Rundgren "Cardiac arrest and therapeutic hypothermia: Prognosis and outcome".
Lund University, 2010
Torsten Danfors "11C Molecular Imaging in focal epilepsy". Uppsala University 2012.
Gustav Torisson "Cognitive impairment in medical inpatients". Lund University, 2015.
Irina Dragancea "Neurological prognostication after cardiac arrest and targeted temperature management". Lund University, 2016.
Hossein Delavaran "Clinical findings and outcome after stroke". Lund University, March 24 2017.
Emil Ygland Rödström "Prognostic subtypes in Parkinson's disease and related disorders. Clinical, genetical and biochemical markers of long term social, motor, and cognitive development". Lund University, November 2021.
Joseph Aked "Stroke epidemiology and outcome in southern Sweden". Lund University, December 2021.
David Larsson Acquired Epilepsy with a Focus on Stroke. Gothenburg University, March 2022.
Klara Andersson "Stigma and socioeconomic outcomes in epilepsy" January 2023. Gothenburg University, January 2023.
Sorina Gorcenco "Clinical and genetic studies on patients and families with ataxias", Lund University, March 2023.
Samuel Håkansson. "Machine learning and big data for personalized epilepsy treatment". Gothenburg University, June 2023.

Suppleant member of the evaluation committee

Ingela Ahnlide "Aspects on skin cancer diagnosis in clinical practice", Lund University 2015

Yulia Sorova "Magnetic Resonance Imaging in Parkinson´s disease and related disorders", Lund University, 2018.

Referee appointments:

Epilepsia, J of Clin Neurol and Neurosurg, Acta Neurol Scand, The Scand J of Clin and Lab Invest, J of Neurology, Epilepsy Research, Läkartidningen, Multiple Sclerosis and Related Disorders and others...

GCP authorized PI in clinical drug trials

1. A multicentre, randomised, double-blind, placebo controlled, phase III study of subcutaneous Rebif (recombinant human interferon-beta) in the treatment of relapsing remitting multiple sclerosis. (Serono)
2. An open randomised, parallel-group comparison of tiagabine BID versus TID as adjunctive treatment of partial seizures in patients with epilepsy. (Novo-Nordisk)
3. A multicenter, double-blind, randomised, parallel-group, positive-controlled trial comparing the efficacy and safety of levetiracetam (1000 to 3000 mg/day oral b.i.d.) to carbamazepine (400 to 1200 mg/day oral b.i.d.) used as monotherapy up to a maximum of 121 weeks in subjects (> 16 years) newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized tonic-clonic seizures. (UCB Pharma)
4. PRI/TOP-INT-11 Topiramate monotherapy comparison trial to standard monotherapy in the treatment of newly diagnosed epilepsy (RWJ-17021-000. (Janssen-Cilag)
5. The Nelly study (Vikt och menstruationsstörningar hos kvinnor med monoterapi mot epilepsi; GlaxoSmithKline)
6. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment. (Parke-Davis)
7. Open multicenter randomized comparison of cognitive effects of lamotrigine and slow-release carbamazepine monotherapy in newly diagnosed patients with partial epilepsy. (Glaxo-Wellcome)
8. Keppra Study N01061. A multi-centre, double-blind, randomized, parallel group, positive-controlled trial comparing the efficacy and safety of levetiracetam to carbamazepine, used as monotherapy in subjects newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized tonic-clonic seizures. (UCB)
9. NS 1209-007. A phase II, multi-centre, single-blinded, randomised, parallel group study to determine the efficacy of NS1209 compared to standard treatment in acute treatment of patients in refractory partial status epilepticus. (NeuroSearch)
10. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of RWJ- 333369 as adjunctive therapy in subjects with partial onset seizures followed by an open-label extension study. (Jansen Cilag)
11. A phase III randomized, multi-centre, double-blind study, to compare the efficacy and safety of zonisamide and carbamazepine as monotherapy, in newly diagnosed partial epilepsy. (Eisai)
12. MAZE STUDY. A phase III randomized, double-blind extension study to assess the long-term safety and to explore the long-term efficacy of zonisamide as monotherapy in newly diagnosed partial seizures. (Eisai).
13. A phase III international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects with partial onset seizures with or without secondary generalization. (UCB)